These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Morphological factors in the prognosis of the treatment results in prostatic cancer].
    Author: Murzaliev AD, Iiazaliev KT, Abdyldaev RA, Sizikov AI.
    Journal: Urol Nefrol (Mosk); 1996; (1):22-5. PubMed ID: 8659037.
    Abstract:
    Investigators from the Research Institute of Oncology and Radiology (Kyrgyzstan) from 1988 to 1994 have conducted a randomized trial entering 122 patients with prostatic cancer. 44 patients received radiation treatment (group 1), 43 patients in addition to radiation were given chemotherapy and estrogens (group 2), 35 patients received drugs and estrogens (group 3). A complete response was registered in 80 (65.5%) patients. 84.2% and 69.8% of them survived 3 and 5 years, respectively. Of 30 patients 24.5%) with partial response 3- and 5-year survival was recorded in 82.8 and 57.3%, respectively. Morphological examination of transrectal prostatic biopsies 3-72 months after the treatment stated the existence of tumor pathomorphosis and unchanged tumor in 111(29.7%) and 42(11.2%) samples. It was found that the above morphological changes had developed throughout 72 months. Their intensity was the greatest within the first after-treatment year. Long-term outcomes proved better in those patients who had no residual tumor and in those who had tumor pathomorphosis during aftertreatment year 1.
    [Abstract] [Full Text] [Related] [New Search]